Veracyte Depreciation And Amortization Over Time

VCYT Stock  USD 41.18  0.19  0.46%   
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Veracyte Performance and Veracyte Correlation.
For more information on how to buy Veracyte Stock please use our How to Invest in Veracyte guide.
  
Depreciation And Amortization is likely to gain to about 28.5 M in 2024.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Veracyte. If investors know Veracyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Veracyte listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.13)
Revenue Per Share
5.644
Quarterly Revenue Growth
0.286
Return On Assets
0.0107
Return On Equity
(0.01)
The market value of Veracyte is measured differently than its book value, which is the value of Veracyte that is recorded on the company's balance sheet. Investors also form their own opinion of Veracyte's value that differs from its market value or its book value, called intrinsic value, which is Veracyte's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Veracyte's market value can be influenced by many factors that don't directly affect Veracyte's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Veracyte's value and its price as these two are different measures arrived at by different means. Investors typically determine if Veracyte is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Veracyte's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Specify up to 10 symbols:

Cross Equities Depreciation And Amortization Analysis

Compare Veracyte and related stocks such as Crinetics Pharmaceuticals, Viridian Therapeutics, and Cytokinetics Depreciation And Amortization Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
201020112012201320142015201620172018201920202021202220232024
CRNX92 K92 K92 K92 K92 K92 K92 K128 K471 K887 K948 K922 K983 K1.1 M760.2 K
CYTK2.8 M1.3 M591 K433 K490 K589 K741 K1.9 M1.2 M5.8 M1.8 M9.6 M8.4 M11.9 M12.5 M
GPCR20 K20 K20 K20 K20 K20 K20 K20 K20 K20 K20 K266.4 K277 K316 K241.8 K
KURAKKKKK20 K31 K30 K10 K10.0194 K558 K759 K849 K891.5 K
PTGX258 K258 K258 K258 K258 K247 K317 K406 K527 K703 K789 K2.8 M3.4 M3.3 M3.5 M
MRUS364.6 K364.6 K364.6 K364.6 K307.7 K211 K246.1 K381.5 K729.8 K(1.6 M)1.4 M1.5 M1.3 M2.5 M2.7 M
REPL122 K122 K122 K122 K122 K122 K122 K109 K148 K533 K4.1 M4.6 M2.4 M2.7 MM
ENTA553 K172 K221 K352 K639 K1.7 M2.1 M2.5 M3.3 M3.6 M3.3 MM2.4 M2.3 MM
SNDX34 K34 K34 K13 K15 K21 K89 K76 K78 K92 K89 K43 K33 K12 K11.4 K
VTYX(1000)(1000)(1000)(1000)(1000)(1000)(1000)(1000)(1000)(1000)M30 K470 K158 K150.1 K
QURE764.7 K764.7 K724.7 K738.8 K1.9 M4.9 M6.1 M8.3 M12.4 M10.2 M10.6 M7.3 M8.5 M11.9 M7.1 M
RCKTKKKK45 K45 K169 K200 K330 K4.1 M1.1 M5.4 M6.3 M7.1 M7.5 M
RYTM17 K17 K17 K20 K500 K500 K144 K223 K442 K834 K690 K1.2 M1.4 M1.8 M1.8 M
SLDB56 K56 K56 K56 K56 K56 K56 K448 K1.6 M2.8 M3.9 MM2.4 M2.6 M2.3 M
MGTX243.1 K243.1 K243.1 K243.1 K243.1 K243.1 K243.1 K679.2 K2.1 M3.3 M4.2 M7.9 M8.7 M13.7 M14.4 M
IDYA391 K391 K391 K391 K391 K391 K391 K391 K886 K1.2 M1.4 M1.7 M2.1 MM4.2 M
ANAB580 K580 K580 K580 K308 K274 K233 K183 K315 K11 M559 K2.1 M2.3 M2.4 MM
KROS304 K304 K304 K304 K304 K304 K304 K304 K304 K438 K605 K898 K1.6 M815 K857.1 K

Veracyte and related stocks such as Crinetics Pharmaceuticals, Viridian Therapeutics, and Cytokinetics Depreciation And Amortization description

The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.

My Equities

My Current Equities and Potential Positions

Veracyte
VCYT
ClassificationHealthcare
LocationCalifornia; U.S.A
ExchangeNASDAQ Exchange
USD 41.18

Additional Tools for Veracyte Stock Analysis

When running Veracyte's price analysis, check to measure Veracyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Veracyte is operating at the current time. Most of Veracyte's value examination focuses on studying past and present price action to predict the probability of Veracyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Veracyte's price. Additionally, you may evaluate how the addition of Veracyte to your portfolios can decrease your overall portfolio volatility.